Contact Information
Emily Wang, Ph.D.
  • Associate Professor, Cancer Biology
  • Co-leader, Molecular and Cellular Biology of Cancer

Research Areas

Professional Experience

• 2013 - present, Associate Professor, Department of Cancer Biology, City of Hope Beckman Research Institute, Duarte, CA
• 2008 - 2013, Assistant Professor, Department of Cancer Biology, City of Hope Beckman Research Institute, Duarte, CA
• 2003 - 2008, Postdoctoral Fellow / Research Assistant Professor, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN
• 2002 - 2003, Postdoctoral Fellow, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
• 1999 - 2002, Ph.D. Candidate, Joint Program, School of Biological Sciences, University of Nebraska-Lincoln
• 1997 - 1999, Ph.D. Candidate, Joint Program, Department of Biochemistry and Molecular Biology, Nankai University, Tianjin, China
• 1996 - 1997, Undergraduate Student / Research Associate, Department of Biochemistry and Molecular Biology, Nankai University, Tianjin, China


  • 2006 - 2008, Vanderbilt University Medical Center, Nashville, TN, Research Assistant Professor, Cancer Biology
  • 2003 - 2006, Vanderbilt University Medical Center, Nashville, TN, Postdoctoral, Cancer Biology
  • 2002 - 2003, Johns Hopkins School of Medicine, Baltimore, MD, Postdoctoral, Viral Oncology
  • 1999 - 2002, University of Nebraska-Lincoln, Lincoln, NE, Ph.D. (joint), Molecular Virology
  • 1997 - 1999, Nankai University, Tianjin, China, Ph.D., Molecular Virology
  • 1993 - 1997, Nankai University, Tianjin, China, B.S., Molecular Biology


• 2006, American Association for Cancer Research (AACR) Scholar-in-Training Award
• 2006, Vanderbilt-Ingram Cancer Center Retreat Most Outstanding Poster
• 2007, American Cancer Society-Institutional Research Grant Award (Vanderbilt)
• 2007, NIH Pathway to Independence Award (K99/R00)
• 2010, California Breast Cancer Research Program Innovative Developmental and Exploratory Award
• 2011, California Breast Cancer Research Program Innovative Developmental and Exploratory Award
• 2012, Breast Cancer Research Foundation-AACR Translational Breast Cancer Research Award
• 2012, City of Hope Women’s Cancer Program “Hope Idol” Award


  •  2005 - present, Member, AACR and AACR-Women in Cancer Research
  •  2007 - 2012, Ad Hoc Reviewer, DOD, Breast Cancer Research Program
  •  2010, Ad Hoc Reviewer, NIH/NCI, Cancer Nanotechnology Program
  •  2011 - 2013, Ad Hoc Reviewer, NIH/NCI, NCI-I Career Development Group
  •  2012 - 2013, Ad Hoc Reviewer, NIH/NCI, Tumor Progression and Metastasis Panel
  •  2013 - present, Ad Hoc Reviewer, NIH/NCI, Cancer Molecular Pathobiology Panel
  •  2013 - present, Standing Member, NIH/NCI, NCI-I Career Development Group


• Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor STF, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, Li AX, Li Z, Gao H, Ren X, Boldin MP, Lin PC, Wang SE*. Cancer Cell. 2014 Apr;25(4):501-15. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Featured Article.
• Chin AR, Wang SE*. Mol Cell Endocrinol. 2014 Jan;382(1):598–602. Cytokines driving breast cancer stemness.

• Wang SE*, Lin RJ*. MicroRNA. 2013 Aug;2(2):137-47. MicroRNA and HER2-overexpressing cancer.

• Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, Luu T, Li AX, Wu X, Ye W, Chen S, Zhou W, Yu Y, Wang YZ, Ren X, Li H, Scherle P, Kuroki Y, Wang SE*. Cancer Res. 2012 Jun;72(11):2768-79. CCL2 mediates crosstalk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells.

• Chandra M, Zang S, Li H, Zimmerman LJ, Champer J, Tsuyada A, Chow A, Zhou W, Yu Y, Gao H, Ren X, Lin RJ, Wang SE*. Mol Cell Biol. 2012 Jun;32(12):2183-95. Nuclear translocation of type I TGF-β receptor confers a novel function in RNA processing.

• Wu X, Somlo G, Yu Y, Palomares MR, Li XA, Zhou W, Chow A, Yen Y, Rossi JJ, Gao H, Wang J, Yuan YC, Frankel P, Li S, Ashing-Giwa KT, Sun G, Wang Y, Smith R, Robinson K, Ren X, Wang SE*. J Transl Med. 2012 Mar;10(1):42. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer.

• Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, Rankin-Gee EK, Wang SE*. Oncogene. 2011 Mar;30(12):1470-80. Transforming growth factor β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM.

• Chow A, Arteaga CL, Wang SE*. J Mammary Gland Biol Neoplasia. 2011 Jun;16(2):81-8. When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene.

• Wang SE*. J Signal Transduction. 2011 Jan;2011(804236):1-8. The functional crosstalk between HER2 tyrosine kinase and TGF-β signaling in breast cancer malignancy.

• Yu Y, Wang Y, Ren X, Tsuyada A, Li A, Liu LJ, Wang SE*. Mol Cancer Res. 2010 Dec;8(12):1633-42. Context-dependent bidirectional regulation of the mutS homolog 2 by transforming growth factor β contributes to chemoresistance in breast cancer cells. Highlighted article.

• Wang SE*, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL*. Cancer Res. 2009 Jan;69(2):475-82. TGF-β induces clustering of HER2 and integrins by activating Src-FAK and receptor association to the cytoskeleton.

• Wang SE, Hinow P, Bryce N, Weaver AM, Estrada L, Arteaga CL, Webb GF. Comput Math Meth Med. 2009 Mar;10(1):71-83. A mathematical model quantifies proliferation and motility effects of TGF-β on cancer cells.

• Wang SE*, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL*. Mol Cell Biol. 2008 Sep;28(18):5605-20. TGF-β engages TACE and ErbB3 to activate PI3K/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.

• Wang SE, Narasanna A, Whitwell CW, Wu FY, Friedman DB, Arteaga CL. J Biol Chem. 2007 Feb;282(8):5661-9. Convergence of p53 and TGF-β signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells.

• Wang SE, Narasanna A, Perez-Torres M, Xiang B, Dugger TC, Wu FY, Yang S, Gazdar AF, Muthuswamy SK, Arteaga CL. Cancer Cell. 2006 Jul;10(1):25-38. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGF receptors and resistance to EGFR tyrosine kinase inhibitors.

• Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. Cancer Res. 2006 Oct;66(19):9591-600. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by TGF-β.


For more information on Dr. Wang's research, please click here